ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 845

Systemic Lupus Erythematosus Immune Complexes Upregulate the Expression of CD319 and CD229 On Plasmacytoid Dendritic Cells

Niklas Hagberg1, Jakob Theorell2, Gunnar V. Alm3, Maija-Leena Eloranta4, Yenan Bryceson2 and Lars Rönnblom4, 1Department of Medical Sciences, SciLife Lab, Rheumatology, Uppsala University, Uppsala, Sweden, Uppsala, Sweden, 2Department of Medicine, Center for Infectious Medicine, Karolinska Institutet, Stockholm, Sweden, 3Department of Biomedical Sciences and Veterinary Public Health, Swedish University of Agricultural Sciences, Uppsala, Sweden, 4Department of Medical Sciences, Section of Rheumatology, Uppsala University, Uppsala, Sweden

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Systemic Lupus Erythematosus - Human Etiology and Pathogenesis I

Session Type: Abstract Submissions (ACR)

Background/Purpose: Patients with SLE have an activated type I interferon (IFN) system due to an ongoing IFN-alpha synthesis by plasmacytoid dendritic cells (pDCs) stimulated by endogenous nucleic-acid containing immune complexes (ICs). The IFN-alpha production by pDC is strongly promoted by NK cells via MIP-1beta and LFA-1-mediated cell contact. In this study we aimed to further identify molecules of importance in the pDC-NK cell cross-talk.

Methods: Healthy donor PBMC were stimulated with medium or IC consisting of purified SLE-IgG and U1snRNP particles (SLE-IC) for 6 h. Surface expression of 45 different molecules was determined on pDCs, CD56dim and CD56brightNK cells by flow cytometry. Regulation of CD319 (CRACC) and CD229 (LY9) was analyzed in isolated or cocultured pDCs and NK cells. Intracellular IFN-alpha was correlated to the expression of CRACC and LY9 on pDCs and the expression of these molecules on different immune cells was compared between SLE patients and healthy controls. Expression of the adaptor molecules SAP and EAT-2 was determined by western blot. The functional role of CRACC and LY9 in pDC and NK cells was investigated.

Results: SLE-IC induced expression of CRACC and LY9 on pDCs, and CRACC on CD56dim NK cells in PBMC (Mean fold increased MFI 3.7, 2.2 and 2.0, respectively). CRACC and LY9 were not regulated in purified pDC but addition of NK cells restored the up-regulation on pDCs. IL-3 or GM-CSF increased the expression of CRACC and LY9 on SLE-IC-stimulated pDCs as efficiently as NK cells. IFN-alpha producing pDCs had a higher expression of CRACC and LY-9 compared to IFN-alpha negative pDCs. Patients with SLE displayed an increased frequency of CRACC+ CD56bright NK cells and B cells (p=0.03; 17±2% vs. 10±2% and p<0.001; 10±3% vs 3±0.3%, respectively, (mean±SEM)) and a decreased frequency of CRACC+ CD56dim NK cells (p=0.01; 59±5% vs. 76±3%, (mean±SEM)). No expression of SAP or EAT-2 was found in pDCs, while NK cells expressed both molecules. Cross-linking CRACC or LY9 by plate-bound mAbs did not affect IFN-alpha production by SLE-IC-stimulated pDCs. Cross-linking CRACC in a redirected cytotoxicity assay resulted in a low frequency of degranulating NK cells, whereas co-ligation of CRACC together with DNAM-1 (CD226) significantly increased the degranulation (4% and 29% CD107a+ CD56dimNK cells, respectively).

Conclusion: SLE-ICs up-regulates the expression of the costimulatory molecules CRACC and LY9 on pDCs and these molecules also have an increased expression on IFN-alpha producing pDCs. Because these SLAM molecules are self-ligands and involved in the activation of several types of immune cells, the expression on both pDCs and NK cells might facilitate the pDC-NK cell interaction and the function of these cells. In contrast to the positive signal delivered by CRACC and LY9 to NK cells, the lack of SAP and EAT-2 adaptor molecules in pDCs suggests an inhibitory function in these cells. The precise roles of CD319 and LY9 in the autoimmune disease process remains to be established, but are important to clarify given the altered expression of CRACC in SLE on both B cells and NK cells.


Disclosure:

N. Hagberg,
None;

J. Theorell,
None;

G. V. Alm,
None;

M. L. Eloranta,
None;

Y. Bryceson,
None;

L. Rönnblom,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/systemic-lupus-erythematosus-immune-complexes-upregulate-the-expression-of-cd319-and-cd229-on-plasmacytoid-dendritic-cells/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology